AC-260,584

AC-260,584

AC-260,584 is a chemical compound that has been studied for its potential effects on the central nervous system. It is primarily known for its role as a selective agonist of the α7 nicotinic acetylcholine receptor (nAChR), which is a subtype of nicotinic receptors that are widely distributed in the brain and are involved in cognitive processes such as learning and memory.

Chemical Structure and Properties

AC-260,584 is a synthetic compound with a specific chemical structure that allows it to interact selectively with the α7 nAChR. The molecular formula of AC-260,584 is C13H14N2O2, and it has a molecular weight of 230.26 g/mol. The compound is characterized by its ability to cross the blood-brain barrier, making it a candidate for central nervous system activity.

Mechanism of Action

The primary mechanism of action of AC-260,584 involves its binding to the α7 nicotinic acetylcholine receptor. This receptor is a ligand-gated ion channel that, when activated, allows the flow of cations such as calcium (Ca2+) and sodium (Na+) into the neuron. Activation of α7 nAChRs by AC-260,584 can lead to enhanced synaptic transmission and modulation of neurotransmitter release, which are critical for cognitive functions.

Pharmacological Effects

Studies have shown that AC-260,584 can enhance cognitive performance in animal models. It has been observed to improve memory and learning in tasks that are dependent on the hippocampus, a brain region crucial for these cognitive processes. The compound's ability to enhance cholinergic signaling is thought to underlie these effects.

Potential Therapeutic Applications

Given its cognitive-enhancing properties, AC-260,584 has been investigated as a potential therapeutic agent for neurodegenerative diseases such as Alzheimer's disease, where cholinergic deficits are a hallmark. Additionally, its role in modulating synaptic plasticity suggests potential applications in treating cognitive impairments associated with schizophrenia and other psychiatric disorders.

Safety and Toxicology

The safety profile of AC-260,584 is still under investigation. Preliminary studies suggest that it is well-tolerated at doses that are effective in enhancing cognitive function. However, comprehensive toxicological studies are necessary to fully understand its safety in humans.

Research and Development

AC-260,584 is currently in the research phase, with ongoing studies aimed at elucidating its full pharmacological profile and therapeutic potential. Researchers are particularly interested in its effects on synaptic plasticity and its ability to modulate neuroinflammatory processes.

Also see

• Nicotinic acetylcholine receptor
• Cognitive enhancer
• Alzheimer's disease
• Neurotransmitter
• Synaptic plasticity